InvestorsHub Logo
Followers 68
Posts 11751
Boards Moderated 1
Alias Born 01/09/2007

Re: None

Friday, 11/18/2022 10:06:11 AM

Friday, November 18, 2022 10:06:11 AM

Post# of 83
ok, so i'm hearing the $200k per treatment is spooking investors. And maybe it should. This drug doesn't cure anything. just delays a diagnosis for a year or so. the pricing is bad for a non-curative drug. seriously, if it's not one thing it's another with this company. every other pharma stock that gets approval of a novel drug runs several hundreds of percents